chloroquine has been researched along with loxiglumide in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fukumoto, M; Hayashi, H; Imamura, M; Kawabata, K; Manabe, T; Masai, Y; Morimoto, H; Nio, Y; Tsubono, M | 1 |
3 other study(ies) available for chloroquine and loxiglumide
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
Topics: Animals; Cell Division; Chloroquine; Cholecystokinin; DNA; Esters; Gabexate; Guanidines; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organ Culture Techniques; Pancreatic Neoplasms; Proglumide; Sincalide; Transplantation, Heterologous | 1993 |